Deutsche Bank analyst Emmanuel Papadakis upgraded Sandoz (SDZNY) to Buy from Hold with a price target of CHF 42, up from CHF 36. The company’s ...
Pharmaceutical Technology on MSN8d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
Pharmalittle: We’re reading about lower Wegovy prices, a dispute over Merck’s Keytruda, and more
Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...
Morgan Stanley lowered the firm’s price target on Sandoz (SDZNY) to CHF 38 from CHF 41 and keeps an Equal Weight rating on the shares.Optimize ...
Swiss generics and biosimilars giant Sandoz today announced financial results for the full year 2024, showing that sales were ...
53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology ...
Richard Saynor, CEO of Sandoz, said: “We delivered strong results in our first full year as an independent company. At the same time, we made excellent progress in transforming the business ...
Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company") today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback